Last reviewed · How we verify

Local OPV

GlaxoSmithKline · Phase 3 active Biologic

Local OPV is an oral polio vaccine that provides immunization against poliovirus through oral administration of live attenuated virus.

Local OPV is an oral polio vaccine that provides immunization against poliovirus through oral administration of live attenuated virus. Used for Poliomyelitis prevention.

At a glance

Generic nameLocal OPV
Also known asoral poliovirus vaccine
SponsorGlaxoSmithKline
Drug classLive attenuated vaccine
TargetPoliovirus (types 1, 2, and/or 3)
ModalityBiologic
Therapeutic areaImmunology / Infectious Disease
PhasePhase 3

Mechanism of action

OPV (Oral Polio Vaccine) contains live attenuated poliovirus strains that replicate in the intestinal tract, stimulating both mucosal and systemic immune responses. This generates antibodies and cellular immunity against wild-type poliovirus. The 'local' designation may refer to a regionally-adapted or locally-produced formulation by GSK.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: